World's Best Scientists 2026 revealed!
Satoshi Morita

Satoshi Morita

D-Index & Metrics

Medicine

D-Index
93
Citations
45308
World Ranking
10679
National Ranking
303

Satoshi Morita publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Satoshi Morita sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 954 publications — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Satoshi Morita D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Satoshi Morita sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 93 D-Index — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Satoshi Morita is a researcher affiliated with Kyoto University in Japan specializing in medicine, with a significant focus on oncology. Their scholarly work encompasses various subfields including oncology, pulmonary and respiratory medicine, cancer research, surgery, and molecular biology.

The main topics covered in their research include:

  • Lung Cancer Treatments and Mutations
  • Colorectal Cancer Treatments and Studies
  • Cancer Treatment and Pharmacology
  • HER2/EGFR in Cancer Research
  • Breast Cancer Treatment Studies
  • Gastric Cancer Management and Outcomes
  • Advanced Breast Cancer Therapies

Satoshi Morita has contributed to a number of research articles published in prominent journals. Some recent representative publications include:

  • Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor, 2021, JAMA Oncology
  • International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO-GC-1), 2021, Annals of Gastroenterological Surgery
  • Validation Study of the International Association for the Study of Lung Cancer Histologic Grading System of Invasive Lung Adenocarcinoma, 2021, Journal of Thoracic Oncology
  • Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC, 2021, Journal of Thoracic Oncology
  • Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR, 2022, Journal of Clinical Oncology

The frequent co-authors collaborating with Morita are:

  • Masakazu Toi
  • Norikazu Masuda
  • Shinji Ohno
  • Kunihiko Kobayashi
  • Toshimi Takano

The primary journals where Morita's work is published consist of:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • International Journal of Clinical Oncology
  • Cancer Research
  • Journal of Thoracic Oncology

This profile reflects an active research trajectory centered on critical aspects of cancer treatment and molecular oncology, particularly in lung and gastric cancers, as well as targeted therapies related to EGFR mutations. The scientist maintains a broad collaboration network and regularly publishes in high-impact clinical oncology journals.

Best Publications

  • Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

    Makoto Maemondo;Akira Inoue;Kunihiko Kobayashi;Shunichi Sugawara

  • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

    Tetsuya Mitsudomi;Satoshi Morita;Yasushi Yatabe;Shunichi Negoro

  • Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

    Junzo Hamanishi;Masaki Mandai;Takafumi Ikeda;Manabu Minami

  • Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model

    Tetsuhiro Kikuchi;Asuka Morizane;Daisuke Doi;Hiroaki Magotani

  • First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy

    Akira Inoue;Kunihiko Kobayashi;Kazuhiro Usui;Makoto Maemondo

  • Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

    A. Inoue;K. Kobayashi;M. Maemondo;S. Sugawara

  • Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

    Haruhiro Saito;Tatsuro Fukuhara;Naoki Furuya;Kana Watanabe

  • Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial

    Shuichi Hironaka;Shinya Ueda;Hirofumi Yasui;Tomohiro Nishina

  • Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.

    Yukio Hosomi;Satoshi Morita;Shunichi Sugawara;Terufumi Kato

  • Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization.

    Manabu Morimoto;Kazushi Numata;Masaaki Kondou;Akito Nozaki

  • Sentinel Node Mapping for Gastric Cancer: A Prospective Multicenter Trial in Japan

    Yuko Kitagawa;Hiroya Takeuchi;Yu Takagi;Shoji Natsugoe

  • Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

    Jun Imagawa;Hideo Tanaka;Masaya Okada;Hirohisa Nakamae

  • Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease.

    S. Miyatake;N. Miyake;H. Touho;A. Nishimura-Tadaki

  • Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.

    Yasuhide Yamada;Daisuke Takahari;Hiroshi Matsumoto;Hideo Baba

  • Determining the effective sample size of a parametric prior

    Satoshi Morita;Peter F. Thall;Peter Müller

  • Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)

    Kei Muro;Narikazu Boku;Yasuhiro Shimada;Akihito Tsuji

  • Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.

    Shuichi Izumoto;Akihiro Tsuboi;Yoshihiro Oka;Tsuyoshi Suzuki

  • Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations

    Satoshi Morita;Isamu Okamoto;Kunihiko Kobayashi;Koichi Yamazaki

  • Frequency of and variables associated with the EGFR mutation and its subtypes

    Tomoaki Tanaka;Masaru Matsuoka;Akihisa Sutani;Akihiko Gemma

  • Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

    Kentaro Yamazaki;M. Nagase;H. Tamagawa;S. Ueda

Frequent Co-Authors

Masakazu Toi
Masakazu Toi Kyoto University
Yasuhiro Kodera
Yasuhiro Kodera Nagoya University
Kazuhiko Nakagawa
Kazuhiko Nakagawa Kindai University
Isamu Okamoto
Isamu Okamoto Kyushu University
Narikazu Boku
Narikazu Boku St. Marianna University School of Medicine
Yasuo Ohashi
Yasuo Ohashi Chuo University
Itaru Endo
Itaru Endo Yokohama City University
Toshihiro Nukiwa
Toshihiro Nukiwa Tohoku University
Kei Muro
Kei Muro National Cancer Research Institute, UK
Hideo Baba
Hideo Baba Kumamoto University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring healthcare careers isn’t limited to traditional, campus-based medical programs. Many students are finding flexibility and affordability through online degrees that lead to rewarding positions in the medical field. For registered nurses looking to advance, consider some of the cheapest accredited online rn to bsn programs to earn your bachelor’s degree without heavy financial pressure.

If you’re interested in the nurse practitioner route but don’t already have a nursing background, direct entry np programs for non nurses online offer a faster way to transition into advanced nursing roles.

Those starting out in nursing can check out online adn programs, which generally have lower barriers to entry and prepare students for RN licensure efficiently.

Interested in the administrative side of healthcare? Choose from the best online medical billing and coding schools to start a flexible, in-demand career supporting medical practices and health systems.

Best Scientists Citing Satoshi Morita

Trending Scientists

Recently Published Articles